Once all fields are completed, review the entire form for any missing information or errors
These insights transform hair loss treatment from a trial-and-error approach to a targeted, evidence-based strategy
Such doses in humans would be fatal and one would expect the same in C

NAD First When: The primary complaint is fatigue, low energy, or feeling depleted for no identifiable reason Brain fog, difficulty with memory recall, or cognitive slowing that is affecting work or daily function Post-viral recovery (Long COVID, post-Lyme, or similar) where systemic cellular function feels compromised The patient wants a broad, foundational energy intervention before layering anything specific on top Peptides First When: The concern is specific and localized: hair thinning, skin laxity, tendon injury, gut inflammation, or body composition The patient wants to optimize performance in the gym, including muscle gain and fat loss (CJC/Ipamorelin, Tesamorelin, MOTS-C) The goal is targeted repair, for example post-procedure healing or scar reduction The patient is already energetic but wants to enhance a specific system or tissue Combination When: Fatigue AND difficulty concentrating: NAD + Semax addresses both the cellular energy deficit and the cognitive signaling layer Fatigue AND skin/hair concerns: NAD + GHK-Cu covers the systemic energy layer and the specific tissue signaling layer simultaneously The patient has multiple complaints that clearly fall into different categories Optimization patients who want to address cellular health comprehensively rather than one concern at a time What Patients Feel: NAD vs

PCa incidence per 10,000 patient-years in cohorts 1 and 2 was 54.4 and 30.7, respectively, which is lower than 116 reported by the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) and 96.6 reported by the ERSPC ( European Randomized Study of Screening for Prostate Cancer)